Accustem Sciences Inc. (ticker: ACUT) is an OTC-listed pharmaceutical preparations company. DredgeCap's structured extraction of ACUT's SEC filings surfaces 9 active risk signals, including 8 late-filing signals, and 1 auditor-change signal. ACUT reported no tagged revenue in revenue and -$1.76M for the period ending 2025-12-31, with operating cash flow of -$850K. Cash and equivalents stood at $14K (up 176% year-over-year). Total assets of $1.55M are exceeded by total liabilities of $4.95M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
ACUT SEC Filings
Full cached SEC EDGAR filing history for ACUT, grouped by form type and sorted newest-first within each group. 0 filings across 0 form types.
Filings sourced verbatim from SEC EDGAR submissions metadata. “Structured” links route to DredgeCap's per-filing renderer (XBRL-backed financials + cited highlights) when available; the EDGAR link always points to the canonical accession index on sec.gov.